Myers
Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey
Pharmaceutical layoffs, workforce reduction, cost-cutting measures, Bristol Myers Squibb, Kyowa Kirin, New Jersey pharma industry
Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.
FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications
FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase
Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action
Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.
Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis
Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor
Bristol Myers Squibb Partners with BioArctic in $100M Alzheimer’s Deal
Bristol Myers Squibb, BioArctic, Leqembi, Alzheimer’s disease, collaboration, $100M upfront payment
Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, portfolio review, collaboration termination
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics Amid Cost-Cutting Measures
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, cost-cutting, strategic productivity initiative, portfolio prioritization